Evidence map›Paper›PMID 36998633›Full record

ArticleOpen forum infectious diseases2023

Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus.

Samuel R Schnittman, Douglas W Kitch, Talia H Swartz, Tricia H Burdo, Kathleen V Fitch, Sara McCallum, Jacqueline M Flynn, Evelynne S Fulda, Marissa R Diggs, Jack T Stapleton and 11 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02344290. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02344290 phase3completed

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

Ran2015Enrolled7,769Registered outcomes37Posted comparisons40ConditionsCardiovascular Diseases, HIVArmsPitavastatin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting inflammasomes as a therapeutic potential for HIV/AIDS.Cellular and molecular life sciences : CMLS · 2025
    Review
  4. Article
  5. HIV Infection Drives Foam Cell Formation via NLRP3 Inflammasome Activation.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 3 countries.

Samuel R SchnittmanDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9692-4405
Douglas W KitchCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Talia H SwartzDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Tricia H BurdoDepartment of Microbiology, Immunology, and Inflammation and Center for Neurovirology and Gene Editing, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
Kathleen V FitchMetabolism Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Sara McCallumMetabolism Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jacqueline M FlynnDepartment of Microbiology, Immunology, and Inflammation and Center for Neurovirology and Gene Editing, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
Evelynne S FuldaMetabolism Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Marissa R DiggsMetabolism Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jack T StapletonDivision of Infectious Diseases, Department of Medicine, University of Iowa, Iowa City, Iowa, USA.
José L CasadoDepartment of Infectious Diseases, Ramon y Cajal Health Research Institute (IRyCIS), University Hospital Ramon y Cajal, Madrid, Spain.
Jana TaronCardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Judith S CurrierDivision of Infectious Diseases, Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
Markella V ZanniMetabolism Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Carlos MalvestuttoDivision of Infectious Diseases, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Carl J FichtenbaumDivision of Infectious Diseases, Department of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Judith A AbergDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Heather J RibaudoCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Michael T LuCardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pamela S DouglasDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Steven K GrinspoonMetabolism Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Massachusetts General Hospital · USCancer Research And Biostatistics · USIcahn School of Medicine at Mount Sinai · USTemple University · USDuke University · USInstituto Cajal · ESThe Ohio State University Wexner Medical Center · USUniversity of California, Los Angeles · USUniversity of Cincinnati · USUniversity of Freiburg · DEUniversity of Iowa · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
REPRIEVE COVID-19 Administrative SupplementU01HL123336 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI DOUGLAS, PAMELA SUSAN, GRINSPOON, STEVEN K. · 2014 to 2021
$52.4M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M
UCLA AIDS Prevention and Treatment Clinical Trials UnitU01AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2007 to 2011
$13.9M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
REPRIEVE - DCCU01HL123339 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LU, MICHAEL TSE-YIN, RIBAUDO, HEATHER JANE · 2014 to 2019
$6.0M
BLRD VA I01 BX000207NHLBI NIH HHS R01 HL141132NHLBI NIH HHS U01 HL123336NHLBI NIH HHS U01 HL123339NHLBI NIH HHS U24 HL164284NIAID NIH HHS K24 AI157882NIAID NIH HHS R21 AI152833NIAID NIH HHS T32 AI007387NIAID NIH HHS U01 AI069424NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI069501NIAID NIH HHS UM1 AI106701NIDA NIH HHS R01 DA052255NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

Background: Inflammasome activation is increased in people with human immunodeficiency virus (PWH), but its relationship with coronary plaque is poorly understood in this setting. Methods: In a large human immunodeficiency virus cardiovascular prevention cohort, relationships between caspase-1, interleukin (IL)-1β, and IL-18 and coronary plaque indices were assessed by multivariate logistic regression. Results: Higher IL-18 and IL-1β were associated with Leaman score, an integrative measure of plaque burden and composition. Conclusions: As Leaman score >5 is associated with cardiovascular events in the general population, future work is needed to determine how the inflammasome relates to events and whether strategies to reduce its activation affect events or plaque progression among PWH.

Indexed as

atherosclerosisHIVinflammasomeLeaman score

Identifiers

PMID36998633
PMCPMC10043127
OpenAlexW4322726636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.